The platform developed during an initiative managed by BioMed X with input from Roche uses field effect sensors to detect several different types of analytes.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
Erada Technology Alliance said the Global Health Innovative Technology Fund grant facilitates production, testing, and validation trials for the rapid test for malaria.
The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
The platform detected clinically relevant concentrations of zinc, a biomarker for a nutritional deficiency that kills 100,000 children under the age of 5 worldwide each year.
Long-term infection with the parasite, which is primarily found in Asia, can lead to a form of bile duct cancer called cholangiocarcinoma.
For the first time ever, the center is funding the development of diagnostic systems — specifically for the development of three devices to detect the infection.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The firm said it anticipates launching the platform in Europe next year and completing its first round of external financing in the first quarter of 2020.
Unlike existing methods for sepsis diagnosis, which rely on the use of a single marker, Mologic's technology is based on six undisclosed markers.
An investigator for the study said that the sensing platform correctly identified all of the patients that were non-responders to anti-PD-1 immunotherapies.
The algorithm uses age, sex, and information about troponin concentrations in patients to determine the likelihood of a heart attack.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
According to industry groups, some vendors are reporting providers have returned POC testing systems because the economics of using them no longer makes sense.
The firm said the clearance authorizes use of its smartphone-based albumin-to-creatinine ratio test by healthcare professionals at the point of care.
Antelope's founder said that being spun off by MyCartis gives his company the focus it needs to launch tests for use in homes and doctors' clinics.
A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.
The firm said that its rapid point-of-care test enables immediate drug adjustments by measuring levels of clozapine, an antipsychotic drug, in a finger prick of blood.
Abionic will conduct all premarket process requirements for the test, while Genentech will fund the clinical and regulatory costs associated with the test.